CytoGenix, Inc. Announces Notice of Allowance in Australia for Single Stranded DNA Expression Vector Patent

HOUSTON--(BUSINESS WIRE)--CytoGenix, Inc. (OTCBB:CYGX) announced today it has received a notice of allowance for a patent on its original single stranded DNA expression plasmid vectors in Australia. The patent, entitled “Production of ssDNA in vivo,” claims both compositions and methods for using the single stranded DNA expression vectors. The subject matter includes several variations of the expression vector system for inducing cells to produce specifically designed single strands of DNA which may be used in antisense, aptamer, triplex or DNA enzyme applications. The claimed system provides a more advanced and flexible approach for using the Company’s proprietary ssDNA expression system.